e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Royalty Pharma plc - Class A Ordinary Shares
(NQ:
RPRX
)
51.80
+0.10 (+0.19%)
Streaming Delayed Price
Updated: 11:59 AM EDT, May 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
768,628
Open
51.69
Bid (Size)
51.80 (100)
Ask (Size)
51.81 (400)
Prev. Close
51.70
Today's Range
51.58 - 52.02
52wk Range
32.15 - 52.15
Shares Outstanding
388,132,400
Dividend Yield
1.81%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions
Today 1:33 EDT
Royalty Pharma’s first quarter results surpassed Wall Street’s revenue and adjusted EBITDA expectations, driven by robust growth across its diversified royal...
Via
StockStory
Topics
Earnings
Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally
↗
May 10, 2026
Centerra Gold operates integrated mining projects in North America and Turkey, generating revenue from gold, copper, and molybdenum sales.
Via
The Motley Fool
Performance
YTD
+33.3%
+33.3%
1 Month
+7.0%
+7.0%
3 Month
+17.2%
+17.2%
6 Month
+33.0%
+33.0%
1 Year
+55.3%
+55.3%
More News
Read More
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge
↗
May 08, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Supply Chain
Royalty Pharma (NASDAQ:RPRX) Beats Q1 Estimates and Raises Guidance, Fueling Strong Momentum
↗
May 06, 2026
Via
Chartmill
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment
↗
March 27, 2026
Via
Chartmill
ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout
↗
March 18, 2026
Via
Chartmill
Royalty Pharma to present at upcoming investor conferences
May 07, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript
↗
May 06, 2026
Via
The Motley Fool
Royalty Pharma reports first quarter 2026 results
May 06, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
May 04, 2026
Via
StockStory
Topics
Artificial Intelligence
3 Unpopular Stocks We’re Skeptical Of
April 22, 2026
Via
StockStory
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
April 21, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Second Quarter 2026 Dividend
April 17, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
April 15, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
April 10, 2026
Via
StockStory
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest
April 07, 2026
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
1 Value Stock for Long-Term Investors and 2 Facing Challenges
April 03, 2026
Via
StockStory
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm
March 31, 2026
Via
StockStory
Topics
Energy
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
March 30, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
March 26, 2026
Via
Finterra
Topics
Economy
Initial Public Offering
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?
March 25, 2026
Via
StockStory
Topics
Artificial Intelligence
Stocks
Supply Chain
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
March 23, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Expansion of Leadership Team
March 17, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
March 02, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
March 02, 2026
From
Royalty Pharma plc
Via
GlobeNewswire
Frequently Asked Questions
Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?
Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.
What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?
Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?
The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market
What is the current price of Royalty Pharma plc - Class A Ordinary Shares?
The current price of Royalty Pharma plc - Class A Ordinary Shares is 51.80
When was Royalty Pharma plc - Class A Ordinary Shares last traded?
The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 05/13/26 11:59 AM ET
What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?
The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 20.11B
How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?
Royalty Pharma plc - Class A Ordinary Shares has 20B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.